Involvement of substance P and the NK-1 receptor in human pathology (Q34413850)

2 August 2017

Involvement of substance P and the NK-1 receptor in human pathology (English)

1 reference

2 August 2017

0 references

0 references

Miguel Muñoz

1

1 reference

PubMed ID

24705689

2 August 2017

Rafael Coveñas

series ordinal

2

1 reference

2 August 2017

6 April 2014

1 reference

2 August 2017

1 reference

2 August 2017

46

1 reference

2 August 2017

7

1 reference

2 August 2017

1727-1750

1 reference

https://scigraph.springernature.com/pub.10.1007/s00726-014-1736-9

2 August 2017

0 references

cites work

Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptor antagonists protect mice from CD95- and tumor necrosis factor-alpha-mediated apoptotic liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Recurrent major depressive disorder: Imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

A ligand-receptor pair that triggers a non-apoptotic form of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurogenic exacerbation of microglial and astrocyte responses to Neisseria meningitidis and Borrelia burgdorferi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Prophylactic and therapeutic targeting of the neurokinin-1 receptor limits neuroinflammation in a murine model of pneumococcal meningitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The distribution of substance P immunoreactive fibers in the rat central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The role of substance P in stress and anxiety responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Tachykinin receptors as therapeutic targets in stress-related disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Cell motility through plasma membrane blebbing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Natural killer cell functions mediated by the neuropeptide substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P antagonists in substantia nigra are anticonvulsant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Cell proliferation associated with actions of the substance P/NK-1 receptor complex in keratocystic odontogenic tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Tachykinins regulate the function of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Measles virus-substance P receptor interactions. Possible novel mechanism of viral fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptor antagonist treatment protects mice against lung injury in polymicrobial sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptor antagonist treatment in polymicrobial sepsis: molecular insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

NK1 (substance P) receptor antagonists--why are they not analgesic in humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Dense plexus of substance P immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neuropeptides--an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P: a pioneer amongst neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Proinflammatory tachykinins that signal through the neurokinin 1 receptor promote survival of dendritic cells and potent cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Involvement of peripherally released substance P and calcitonin gene-related peptide in mediating mechanical hyperalgesia in a traumatic neuropathy model of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Potentiation of the anticonvulsant efficacy of sodium channel inhibitors by an NK1-receptor antagonist in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Identification of a delta isoform of preprotachykinin mRNA in human mononuclear phagocytes and lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Valproic acid inhibits substance P-induced activation of protein kinase C epsilon and expression of the substance P receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Distribution of the substance P receptor (NK-1 receptor) in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 enables measles virus trans-synaptic spread in neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a Rho/Rho-associated coiled-coil kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

A new frontier in the treatment of cancer: NK-1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

NK-1 receptor antagonists: a new paradigm in pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Involvement of substance P and the NK-1 receptor in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Safety of neurokinin-1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonist, L-732,138.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Rewarding effects of opiates are absent in mice lacking the receptor for substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The role of substance P in inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Preprotachykinin-A gene products are key mediators of lung injury in polymicrobial sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P antagonist improves both obesity and asthma in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Striatal dopamine and glutamate release: effects of intranigral injections of substance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptor antagonists inhibit the recruitment of opioid-containing leukocytes and impair peripheral antinociception

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P causes seizures in neurocysticercosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Targeting opioid and neurokinin-1 receptors to treat alcoholism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Immunopathogenic mechanisms of HIV infection: cytokine induction of HIV expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P receptor-mediated chemotaxis of human monocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; a possible neurophysiological and neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Analysis of the mechanism of histamine release induced by substance P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Kainic acid induced seizures: changes in somatostatin, substance P and neurotensin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Peripheral substance P and neurokinin-1 receptors have a role in inflammatory and neuropathic orofacial pain models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P in the corneal stroma regulates the severity of herpetic stromal keratitis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Behavioral and pharmacological validation of the gerbil forced-swim test: effects of neurokinin-1 receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Biochemical characterization and autoradiographic localization of central substance P receptors using [125I]physalaemin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Neurokinin-1 (NK-1) receptor antagonists abrogate methamphetamine-induced striatal dopaminergic neurotoxicity in the murine brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

A tachykinin NK1 receptor antagonist, CP-122,721-1, attenuates kainic acid-induced seizure activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00726-014-1736-9

10.1007/S00726-014-1736-9

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

24705689